Search Results

Deals

Aeterna Zentaris and Ceapro Complete Merger Transaction

Aeterna Zentaris Inc. and Ceapro Inc. are pleased to announce the successful completion and closing of their all-stock merger of equals transaction, which was previously announced by Aeterna and Ceapro in their joint press release of December 14, 2023.

June 3, 2024

·

10 min read

Deals

Aeterna Zentaris Announces Details Regarding Transaction with Ceapro

Aeterna Zentaris Inc. announces that it has finalized certain details regarding the previously announced merger of equals transaction (the “ Transaction ”) with Ceapro Inc. (“ Ceapro ”).

May 17, 2024

·

11 min read

Business

Aeterna Zentaris Reports First Quarter 2024 Financial Results

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the quarter ended March 31, 2024.

May 14, 2024

·

9 min read

Aeterna Zentaris Announces Effective Date of Share Consolidation

Aeterna Zentaris Inc. announces that it has filed articles of amendment to effect the previously announced share consolidation of its issued and outstanding common shares on the basis of one post-Consolidation Common Share for every four pre-Consolidation Common Shares.

May 1, 2024

·

10 min read

Deals

Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris

Aeterna Zentaris Inc. and Ceapro Inc. are pleased to announce that the Court of King’s Bench of Alberta has issued a final order approving the arrangement described in the previously announced definitive agreement to combine the operations of Ceapro and Aeterna in an all-stock merger of equals transaction.

March 28, 2024

·

9 min read

Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date

Aeterna Zentaris Inc. announced that it is making an application for an order pursuant to section 133 of the Canada Business Corporations Act extending the time for the Company to call and hold its annual meeting of its shareholders to a date that is not later than July 31, 2024.

May 29, 2024

·

6 min read

Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Aeterna Zentaris Inc. announced the clinical completion of its Phase 3 safety and efficacy study AEZS-130-P02 evaluating macimorelin for the diagnosis of Childhood Onset Growth Hormone Deficiency.

June 13, 2024

·

7 min read

Deals

Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings

Aeterna Zentaris Inc. and Ceapro Inc. are pleased to announce that securityholders of both biopharmaceutical development companies approved the all-stock merger of equals transaction at their respective special meetings.

March 12, 2024

·

11 min read

Business

Aeterna Zentaris to Participate at the Virtual Investor Ask the CEO Conference

Aeterna Zentaris Inc. announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris will participate at the Virtual Investor Ask the CEO Conference on Wednesday, October 25, 2023 at 10:00 AM ET.

October 11, 2023

·

2 min read

Business

Aeterna Zentaris Reports Third Quarter 2023 Financial Results

Aeterna Zentaris Inc. reported its financial and operating results for the quarter ended September 30, 2023.

November 9, 2023

·

9 min read